{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T18:06:22Z","timestamp":1786125982137,"version":"build-2736575974"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Indonesia diagnoses roughly 24,000 multidrug-resistant tuberculosis (MDR-TB) cases each year, 8% of the world\u2019s total. Conventional treatment runs 18\u201324 months, costs US$7,142\u20139,000 per patient, and succeeds in only 59% of cases. The WHO endorsed Bedaquiline-Pretomanid-Linezolid (BPaL) regimen has shown over 89% efficacy in controlled trials, but real-world health economic data from low- and middle-income countries remain scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of 84 patients with MDR-TB, rifampicin-resistant TB (RR-TB), or pre-extensively drug-resistant TB (pre-XDR-TB) treated at Persahabatan Hospital, Jakarta, between 2021 and 2024. We compared treatment success, costs, and operational metrics against historical controls from 2018\u20132020. Statistical methods included chi-square tests, multivariate logistic regression, and incremental cost-effectiveness ratio (ICER) calculations, with sensitivity analyses across \u00b120% cost and \u00b110% efficacy ranges.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>BPaL achieved 77.4% treatment success (65\/84 patients) compared with 59% in historical controls (p\u2009&lt;\u20090.01). Per-patient costs dropped 67%, from US$7,142\u20139,000 to US$2,310. The ICER was US$311.4 per additional treatment success. Hospital stays shortened by 60% (10 versus 25 days; p\u2009&lt;\u20090.01), and adherence climbed from 70% to 95.2% (p\u2009&lt;\u20090.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>BPaL is effective, affordable, and ready to scale. Integrating it into Indonesia\u2019s Jaminan Kesehatan Nasional (JKN) framework and expanding decentralised diagnostics could accelerate progress towards WHO End TB 2030 targets. Our findings offer a replicable model for other low- and middle-income settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0351836","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:36:37Z","timestamp":1786124197000},"page":"e0351836","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Catalysing tuberculosis elimination in Indonesia: Health economic and policy insights from the BPaL regimen"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0235-9425","authenticated-orcid":true,"given":"Abdullah","family":"Antaria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidy","family":"Agustina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratnawati","family":"Ratnawati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sita Laksmi","family":"Andarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diah","family":"Handayani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"pone.0351836.ref001","volume-title":"Global tuberculosis report 2023","author":"World Health Organization","year":"2023"},{"key":"pone.0351836.ref002","volume-title":"National tuberculosis control programme: annual report 2022","author":"Ministry of Health R of I","year":"2023"},{"issue":"6","key":"pone.0351836.ref003","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4269\/ajtmh.2010.09-0447","article-title":"The incremental cost-effectiveness of engaging private practitioners to refer tuberculosis suspects to DOTS services in Jogjakarta, Indonesia","volume":"82","author":"Y Mahendradhata","year":"2010","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"pone.0351836.ref004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40249-017-0382-3","article-title":"Catastrophic total costs in tuberculosis-affected households and their determinants since Indonesia\u2019s implementation of universal health coverage","volume":"7","author":"A Fuady","year":"2018","journal-title":"Infect Dis Poverty"},{"key":"pone.0351836.ref005","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jix379","article-title":"Quality tuberculosis care in indonesia: using patient pathway analysis to optimize public-private collaboration","volume":"216","author":"A Surya","year":"2017","journal-title":"J Infect Dis"},{"key":"pone.0351836.ref006","doi-asserted-by":"crossref","first-page":"29866","DOI":"10.3402\/gha.v9.29866","article-title":"The path to impact of operational research on tuberculosis control policies and practices in Indonesia","volume":"9","author":"A Probandari","year":"2016","journal-title":"Glob Health Action"},{"issue":"10202","key":"pone.0351836.ref007","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0140-6736(19)31882-3","article-title":"Management of drug-resistant tuberculosis","volume":"394","author":"C Lange","year":"2019","journal-title":"Lancet"},{"key":"pone.0351836.ref008","article-title":"The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis","author":"K Dheda","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"10","key":"pone.0351836.ref009","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"F Conradie","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0351836.ref010","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"F Conradie","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0351836.ref011","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1183\/13993003.00724-2015","article-title":"Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis","volume":"47","author":"AS Pym","year":"2016","journal-title":"Eur Respir J"},{"issue":"8","key":"pone.0351836.ref012","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1313865","article-title":"Multidrug-resistant tuberculosis and culture conversion with bedaquiline","volume":"371","author":"AH Diacon","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0351836.ref013","doi-asserted-by":"crossref","first-page":"1700387","DOI":"10.1183\/13993003.00387-2017","article-title":"Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study","volume":"49","author":"SE Borisov","year":"2017","journal-title":"Eur Respir J"},{"key":"pone.0351836.ref014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2020.01.042","article-title":"MDR\/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network","volume":"92","author":"GB Migliori","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"25","key":"pone.0351836.ref015","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"B-T Nyang\u2019wa","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0351836.ref016","first-page":"2000261","article-title":"Should we worry about the pharmacokinetics of the new anti-tuberculosis drugs?","volume":"55","author":"JW Alffenaar","year":"2020","journal-title":"Eur Respir J"},{"issue":"3","key":"pone.0351836.ref017","doi-asserted-by":"crossref","first-page":"2100621","DOI":"10.1183\/13993003.00621-2021","article-title":"Emergence of bedaquiline resistance in a high tuberculosis burden country","volume":"59","author":"E Chesov","year":"2022","journal-title":"Eur Respir J"},{"issue":"8","key":"pone.0351836.ref018","article-title":"Comparative effectiveness of BPaL and standard of care for treatment of highly drug-resistant tuberculosis: a modelling study","volume":"11","author":"NA Menzies","year":"2023","journal-title":"Lancet Glob Health"},{"issue":"3","key":"pone.0351836.ref019","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S2213-2600(15)00063-6","article-title":"Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies","volume":"3","author":"A Zumla","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"152","key":"pone.0351836.ref020","doi-asserted-by":"crossref","first-page":"190035","DOI":"10.1183\/16000617.0035-2019","article-title":"Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives","volume":"28","author":"E Pontali","year":"2019","journal-title":"Eur Respir Rev"},{"issue":"6","key":"pone.0351836.ref021","doi-asserted-by":"crossref","first-page":"2003300","DOI":"10.1183\/13993003.03300-2020","article-title":"World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update","volume":"57","author":"F Mirzayev","year":"2021","journal-title":"Eur Respir J"},{"issue":"13","key":"pone.0351836.ref022","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","article-title":"A trial of a shorter regimen for rifampin-resistant tuberculosis","volume":"380","author":"AJ Nunn","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"pone.0351836.ref023","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","article-title":"Final analysis of a trial of M72\/AS01E vaccine to prevent tuberculosis","volume":"381","author":"DR Tait","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0351836.ref024","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00100-19","article-title":"Tuberculosis vaccine development: progress in clinical evaluation","volume":"33","author":"SB Sable","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"pone.0351836.ref025","doi-asserted-by":"crossref","first-page":"199","DOI":"10.12688\/f1000research.13588.1","article-title":"Progress and challenges in TB vaccine development","volume":"7","author":"G Voss","year":"2018","journal-title":"F1000Res"},{"issue":"33","key":"pone.0351836.ref026","doi-asserted-by":"crossref","first-page":"13980","DOI":"10.1073\/pnas.0901720106","article-title":"Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics","volume":"106","author":"LJ Abu-Raddad","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"pone.0351836.ref027","doi-asserted-by":"crossref","first-page":"305","DOI":"10.5588\/ijtld.20.0513","article-title":"A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB","volume":"25","author":"CD Tweed","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0351836.ref028","volume-title":"Definitions and reporting framework for tuberculosis \u2013 2013 revision (updated December 2014)","author":"World Health Organization","year":"2014"},{"issue":"10","key":"pone.0351836.ref029","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201909-1874ST","article-title":"Treatment of drug-resistant tuberculosis. An official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"200","author":"P Nahid","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"pone.0351836.ref030","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(17)30205-X","article-title":"Cost-effectiveness of Xpert MTB\/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation","volume":"5","author":"A Vassall","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"11","key":"pone.0351836.ref031","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S1473-3099(16)30259-6","article-title":"The number of privately treated tuberculosis cases in India: an estimation from drug sales data","volume":"16","author":"N Arinaminpathy","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"pone.0351836.ref032","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2471\/BLT.14.138206","article-title":"Thresholds for the cost-effectiveness of interventions: alternative approaches","volume":"93","author":"E Marseille","year":"2015","journal-title":"Bull World Health Organ"},{"issue":"4","key":"pone.0351836.ref033","article-title":"Patient characteristics, drug resistance patterns and treatment outcomes of MDR-TB patients in Revised National TB Control Programme, India: 2013\u20132014","volume":"12","author":"HD Shewade","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"pone.0351836.ref034","doi-asserted-by":"crossref","first-page":"1700061","DOI":"10.1183\/13993003.00061-2017","article-title":"Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses","volume":"50","author":"F Ahmad Khan","year":"2017","journal-title":"Eur Respir J"},{"issue":"2","key":"pone.0351836.ref035","article-title":"Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB\/RIF in South Africa: a retrospective cohort study","volume":"14","author":"H Cox","year":"2017","journal-title":"PLoS Med"},{"issue":"3","key":"pone.0351836.ref036","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3201\/eid2203.151788","article-title":"Factors associated with loss to follow-up during treatment for multidrug-resistant tuberculosis, the Philippines, 2012-2014","volume":"22","author":"TE Tupasi","year":"2016","journal-title":"Emerg Infect Dis"},{"issue":"9","key":"pone.0351836.ref037","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(18)30235-2","article-title":"Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study","volume":"6","author":"K Schnippel","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"5","key":"pone.0351836.ref038","doi-asserted-by":"crossref","first-page":"1800544","DOI":"10.1183\/13993003.00544-2018","article-title":"Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa","volume":"51","author":"O Olayanju","year":"2018","journal-title":"Eur Respir J"},{"issue":"3","key":"pone.0351836.ref039","doi-asserted-by":"crossref","first-page":"1601799","DOI":"10.1183\/13993003.01799-2016","article-title":"Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis","volume":"49","author":"L Guglielmetti","year":"2017","journal-title":"Eur Respir J"},{"issue":"7","key":"pone.0351836.ref040","doi-asserted-by":"crossref","first-page":"766","DOI":"10.5588\/ijtld.17.0840","article-title":"Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia","volume":"22","author":"C Hewison","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"pone.0351836.ref041","doi-asserted-by":"crossref","first-page":"936","DOI":"10.3201\/eid2505.181823","article-title":"Outcomes of bedaquiline treatment in patients with multidrug-resistant tuberculosis","volume":"25","author":"L Mbuagbaw","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"pone.0351836.ref042","first-page":"19","article-title":"Emergence of bedaquiline resistance in multidrug-resistant tuberculosis in Moldova","volume":"97","author":"D Chesov","year":"2020","journal-title":"Int J Infect Dis"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0351836","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:36:44Z","timestamp":1786124204000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0351836"}},"subtitle":[],"editor":[{"given":"Frederick","family":"Quinn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":42,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0351836","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]}}}